PMID- 26870191
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 11
IP  - 1
DP  - 2016 Jan
TI  - Anaplastic lymphoma kinase protein expression predicts micrometastases and 
      prognosis for patients with hepatocellular carcinoma.
PG  - 213-223
AB  - The present study aimed to investigate anaplastic lymphoma kinase (ALK) status in 
      hepatocellular carcinoma (HCC) and to evaluate whether abnormalities in 
      expression were associated with patient prognosis. ALK status was investigated 
      using immunohistochemistry (IHC), reverse transcription-quantitative polymerase 
      chain reaction (RT-qPCR) and fluorescence in situ hybridization (FISH) assays in 
      342 HCC patients. In addition, rapid amplification of complementary DNA 
      ends-coupled PCR sequencing was performed, in order to confirm the presence of 
      ALK abnormalities in patients exhibiting ALK messenger RNA (mRNA) overexpression. 
      The correlation between ALK expression and the clinicopathological features and 
      prognosis of the HCC patients was statistically analyzed. The results of the 
      present study revealed overexpression of ALK protein and mRNA; furthermore, ALK 
      gene copy number gains were observed via IHC (44.7%; 153/342), RT-qPCR (47.4%; 
      162/342) and FISH (32.7%; 112/342) analyses, although ALK rearrangement or 
      mutation was not demonstrated in the results of any of these assays. ALK protein 
      expression levels were significantly associated with hepatitis C virus (HCV) 
      status (P<0.001) and the presence of micrometastases (P=0.011). Within the entire 
      patient cohort, ALK expression was associated with poor progression-free survival 
      (PFS; P=0.041). Subsequent analysis in patient subgroups that demonstrated 
      hepatitis B surface antigen positivity, HCV negativity, stage III-IV disease, 
      recurrence and micrometastasis positivity revealed that overall survival (OS) and 
      PFS were significantly reduced in those patients exhibiting ALK expression 
      compared with those patients who were negative for ALK expression. Multivariate 
      analysis revealed that ALK expression was an independent risk factor for OS 
      (P=0.042) and PFS (P=0.033), particularly for patients with stage III-IV tumors. 
      Thus, ALK may serve as a novel indicator for the metastatic behavior and 
      prognosis of HCC.
FAU - Liu, Jianhua
AU  - Liu J
AD  - Department of Oncology, Cancer Center, Guangdong General Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, Guangdong 510180, P.R. China.
FAU - Jin, Haosheng
AU  - Jin H
AD  - Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, Guangdong 510180, P.R. China.
FAU - Tian, Hongxia
AU  - Tian H
AD  - Medical Research Center, Lung Cancer Institute, Guangdong General Hospital, 
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510180, P.R. China.
FAU - Lian, Guoda
AU  - Lian G
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Sun Yat-Sen 
      University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Chen, Shaojie
AU  - Chen S
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Sun Yat-Sen 
      University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Li, Jiayu
AU  - Li J
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Sun Yat-Sen 
      University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Zhang, Xuchao
AU  - Zhang X
AD  - Medical Research Center, Lung Cancer Institute, Guangdong General Hospital, 
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510180, P.R. China.
FAU - Ma, Dong
AU  - Ma D
AD  - Department of Oncology, Cancer Center, Guangdong General Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, Guangdong 510180, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20151104
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC4727030
OTO - NOTNLM
OT  - anaplastic lymphoma kinase
OT  - clinicopathological characteristics
OT  - hepatocellular carcinoma
OT  - micrometastases
OT  - prognosis
EDAT- 2016/02/13 06:00
MHDA- 2016/02/13 06:01
PMCR- 2015/11/04
CRDT- 2016/02/13 06:00
PHST- 2014/11/12 00:00 [received]
PHST- 2015/09/24 00:00 [accepted]
PHST- 2016/02/13 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/02/13 06:01 [medline]
PHST- 2015/11/04 00:00 [pmc-release]
AID - OL-0-0-3859 [pii]
AID - 10.3892/ol.2015.3859 [doi]
PST - ppublish
SO  - Oncol Lett. 2016 Jan;11(1):213-223. doi: 10.3892/ol.2015.3859. Epub 2015 Nov 4.